PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Public ClinicalTrials.gov record NCT03013491. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody® Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody CLinical Assessment In Man CX-072 clinical trial CX-072 is a Probody® therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are proteolytically-activatable antibodies (Abs) designed to widen the therapeutic index by minimizing drug interaction with normal tissue while retaining anti-tumor activity. Probody therapeutics are "masked" to attenuate binding to target in healthy tissue but can become "unmasked" in the tumor microenvironment by tumor-specific protease activity. PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc.
Study identification
- NCT ID
- NCT03013491
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 196 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 18, 2017
- Primary completion
- Oct 26, 2020
- Completion
- Oct 26, 2020
- Last update posted
- Jun 16, 2025
2017 – 2020
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| PROCLAIM Investigative Site | Los Angeles | California | 90025 | — |
| PROCLAIM Investigative Site | Los Angeles | California | 90033 | — |
| PROCLAIM Investigative Site | New Haven | Connecticut | 06520 | — |
| PROCLAIM Investigative Site | Chicago | Illinois | 60612 | — |
| PROCLAIM Investigative Site | Indianapolis | Indiana | 46202 | — |
| PROCLAIM Investigative Site | Boston | Massachusetts | 02215 | — |
| PROCLAIM Investigative Site | Detroit | Michigan | 48201 | — |
| PROCLAIM Investigative Site | New York | New York | 10016 | — |
| PROCLAIM Investigative Site | New York | New York | 10032 | — |
| PROCLAIM Investigative Site | New York | New York | 10065 | — |
| PROCLAIM Investigative Site | Portland | Oregon | 97213 | — |
| PROCLAIM Investigative Site | Nashville | Tennessee | 37203 | — |
| PROCLAIM Investigative Site | Dallas | Texas | 75230 | — |
| PROCLAIM Investigative Site | Houston | Texas | 77030 | — |
| PROCLAIM Investigative Site | Fairfax | Virginia | 22031 | — |
| PROCLAIM Investigative Site | Madison | Wisconsin | 53579 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03013491, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03013491 live on ClinicalTrials.gov.